Showing results (21-30 of 48) with videos related to

Sort By:
Pageof 5
Current Molecular Medicine|March 20, 2002
The functional and clinical roles of osteopontin in cancer and metastasisK A Furger, R K Menon, A B Tuck, et al.
Cancer Immunology, Immunotherapy : CII|November 1, 1995
High-dose continuous venous infusion of interleukin-2: influence of dose and infusion rate on tumoricidal function and lymphocyte subsetsW C Mertens, D Banerjee, N al-Mutter, et al.
Lancet (London, England)|August 15, 1992
Effect of indomethacin plus ranitidine in advanced melanoma patients on high-dose interleukin-2W C Mertens, V H Bramwell, F Gwadry-Sridhar, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 1, 1995
Phase II study of topotecan (NSC 609 699) in patients with recurrent or metastatic soft tissue sarcomaV H Bramwell, E A Eisenhauer, M Blackstein, et al.
Lancet (London, England)|June 27, 1998
Expression of genes that contribute to proliferative and metastatic ability in breast cancer resected during various menstrual phasesZ Saad, V H Bramwell, S M Wilson, et al.
Cancer Treatment Reports|May 1, 1981
Treatment of advanced soft tissue sarcoma with chlorozotocin: a phase II trial of the EORTC soft tissue and bone sarcoma groupH T Mouridsen, V H Bramwell, J Lacave, et al.
Investigational New Drugs|September 1, 1988
Phase II study of flutamide in patients with metastatic breast cancer. A National Cancer Institute of Canada Clinical Trials Group studyD J Perrault, D M Logan, D J Stewart, et al.
Cancer Treatment Reports|April 1, 1985
Activity of JM9 in advanced ovarian cancer: a phase I-II trialV H Bramwell, D Crowther, S O'Malley, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1986
Cyclophosphamide versus ifosfamide: preliminary report of a randomized phase II trial in adult soft tissue sarcomasV H Bramwell, H T Mouridsen, A Santoro, et al.
European Journal of Cancer & Clinical Oncology|June 1, 1984
Phase II study of amsacrine in refractory lymphomas. A report of the EORTC Early Clinical Trials GroupV H Bramwell, E E Holdener, P Siegenthaler, et al.
Pageof 5